SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

by · The Markets Daily

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) saw unusually large options trading activity on Friday. Traders acquired 21,865 call options on the company. This is an increase of approximately 95% compared to the average volume of 11,198 call options.

Insider Activity

In other news, Director Katherine Bach Kalin acquired 63,400 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were purchased at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the acquisition, the director directly owned 104,400 shares of the company’s stock, valued at $165,996. This represents a 154.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.40% of the stock is owned by insiders.

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of hedge funds have recently made changes to their positions in SLS. Axxcess Wealth Management LLC purchased a new position in shares of SELLAS Life Sciences Group during the third quarter worth approximately $26,000. BNP Paribas Financial Markets increased its stake in shares of SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after buying an additional 9,299 shares during the period. Blair William & Co. IL purchased a new stake in SELLAS Life Sciences Group in the 2nd quarter valued at $35,000. ProShare Advisors LLC acquired a new position in SELLAS Life Sciences Group in the 2nd quarter valued at about $43,000. Finally, Sei Investments Co. purchased a new position in SELLAS Life Sciences Group in the 3rd quarter valued at $43,000. Institutional investors own 17.38% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $7.00.

Read Our Latest Research Report on SLS

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ:SLS traded up $0.06 during midday trading on Friday, hitting $2.40. 2,337,140 shares of the stock were exchanged, compared to its average volume of 2,993,071. The stock has a market capitalization of $341.15 million, a price-to-earnings ratio of -8.55 and a beta of 2.51. SELLAS Life Sciences Group has a 12 month low of $0.85 and a 12 month high of $2.48. The business’s 50-day moving average price is $1.78 and its 200 day moving average price is $1.77.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. As a group, sell-side analysts expect that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

See Also